Cell therapy with placenta-derived mesenchymal stem cells for secondary progressive multiple sclerosis patients in a phase 1 clinical trial

Cell therapy with placenta-derived mesenchymal stem cells for secondary progressive multiple sclerosis patients in a phase 1 clinical trial

Abstract Mesenchymal stem cell (MSC) has attracted significant attention in clinical research due to their immunomodulatory properties and potential to reduce inflammation in autoimmune disorders, such as multiple sclerosis (MS). This study evaluates the safety and feasibility of placenta-derived MS...

Full description

Saved in:
Bibliographic Details
Main Authors: Ameneh Shokati, Mohsen Nikbakht, Mohammad Ali Sahraian, Roghayyeh Saeedi, Elnaz Asadollahzadeh, Nasim Rezaeimanesh, Bahram Chahardouli, Zeinab Gharaylou, Seyed Asadollah Mousavi, Jafar Ai, Abdorreza Naser Moghadasi
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Multiple sclerosis
Placenta-derived mesenchymal stem cells
Cell therapy
Brain mapping
Diffusion tensor imaging
Cognitive and psychological evaluations
Online Access:https://doi.org/10.1038/s41598-025-00590-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-00590-6

Similar Items